Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Juli Smelser

Nurse Practitioner Maumee, OH Nurse Practitioner

NPI 1104075761 CMS profile 10676934

1661 Holland Rd Ste 200, Maumee, OH 43537

Open in the dashboard

General payments

$6,960

241 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Juli Smelser of Maumee, OH is reported in the CMS Open Payments database as having received $6,960 across 241 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,074 76
2024 General $1,382 48
2023 General $966 41
2022 General $834 22
2021 General $1,703 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juli Smelser
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Juli Smelser were reported at $2,074. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Juli Smelser Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,703 $135 $40–$426 $132
2022 $834 $152 $48–$470 $149
2023 $966 $166 $54–$529 $160
2024 $1,382 $173 $55–$556 $164
2025 $2,074 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,044 27 payments
  2. Medtronic, Inc. $810 9 payments
  3. Regeneron Healthcare Solutions, Inc. $563 13 payments
  4. Harmony Biosciences LLC $541 18 payments
  5. GlaxoSmithKline, LLC. $514 28 payments
  6. United Therapeutics Corporation $509 18 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $363 11 payments
  8. Amgen Inc. $268 8 payments
  9. Axsome Therapeutics, Inc. $231 10 payments
  10. Genzyme Corporation $225 13 payments
  11. Other $1,890 86 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,066 233 payments
  2. Travel and Lodging $471 3 payments
  3. Education $423 5 payments
Products named General payments · program years 2021–2025
  1. INTERSTIM $810 9 payments
  2. TEZSPIRE Respiratory $348 10 payments
  3. BREZTRI $336 6 payments
  4. FASENRA $317 8 payments
  5. DUPIXENT Immunology And Inflammation $304 8 payments
  6. TEZSPIRE Inflammation $268 8 payments
  7. DUPIXENT Inflammation And Immunology $258 5 payments
  8. Sunosi $231 10 payments
  9. DUPIXENT Immunology $225 13 payments
  10. WAKIX $208 7 payments
  11. Other $3,789 178 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,608

Median for Nurse Practitioner: 389

Drug cost

$580,541

Median for Nurse Practitioner: $21,885

Branded share of claims

72.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 237 $192,940
Dupixent Pen Dupilumab Brand 33 $123,935
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 75 $61,478
Breo Ellipta Fluticasone/Vilanterol Brand 91 $40,391
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 45 $29,348
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 34 $23,944
Eliquis Apixaban Brand 14 $16,954
Spiriva Respimat Tiotropium Bromide Brand 19 $15,708
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 22 $11,096
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 42 $9,882

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$66,944

Medicare's payments for the services billed

Medicare patients

557

Average age 75

Services billed

976

276 women, 281 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
COPD 60%
Heart failure 52%
Ischemic heart disease 48%
Diabetes 45%
Chronic kidney disease 42%
Atrial fibrillation 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $208
$208 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $109
  • GENZYME CORPORATION $35
$144 33 —
AREXVY
  • GlaxoSmithKline, LLC. $140
$140 — —
Sunosi
  • Axsome Therapeutics, Inc. $123
$123 — —
TEZSPIRE
  • Amgen Inc. $54
  • AstraZeneca Pharmaceuticals LP $21
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record